Published in Ann Intern Med on May 07, 2013
Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology (2014) 2.34
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 2.17
HIV-1 Infection Accelerates Age According to the Epigenetic Clock. J Infect Dis (2015) 1.70
The relationship of physical performance with HIV disease and mortality. AIDS (2014) 1.46
Drinking motives among HIV primary care patients. AIDS Behav (2014) 0.97
Poorly Controlled HIV Infection: An Independent Risk Factor for Liver Fibrosis. J Acquir Immune Defic Syndr (2016) 0.84
Hepatitis C virus infection in the human immunodeficiency virus infected patient. World J Gastroenterol (2014) 0.84
Accelerated epigenetic aging in brain is associated with pre-mortem HIV-associated neurocognitive disorders. J Neurovirol (2015) 0.82
Burden of Liver Disease among Community-Based People Who Inject Drugs (PWID) in Chennai, India. PLoS One (2016) 0.79
Human immunodeficiency virus and liver disease forum 2012. Hepatology (2013) 0.79
Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy. Clin Infect Dis (2016) 0.78
Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients. Open Forum Infect Dis (2015) 0.77
Age and ethnicity in cirrhosis. J Investig Med (2014) 0.77
HCV RNA viral load is independent from CD4 cell count and plasma HIV RNA viral load in immunocompetent HIV-HCV co-infected patients: a 3-years follow-up study. AIDS Res Ther (2014) 0.77
Interaction Between Alcohol Consumption Patterns, Antiretroviral Therapy Type, and Liver Fibrosis in Persons Living with HIV. AIDS Patient Care STDS (2016) 0.77
Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study. Sci Rep (2015) 0.77
CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment. Can J Infect Dis Med Microbiol (2016) 0.75
HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection. BMC Infect Dis (2016) 0.75
HCV treatment in children and young adults with HIV/HCV co-infection in Europe. J Virus Erad (2015) 0.75
C-WORTHY: the beginning of the rise of elbasvir and grazoprevir for the treatment of hepatitis C genotype 1 mono and HIV co-infected patients. Ann Transl Med (2016) 0.75
Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients. Drugs R D (2015) 0.75
Noninvasive Assessment of Liver Fibrosis By Transient Elastography and FIB4/APRI for Prediction of Treatment Response in Chronic Hepatitis C-An Experience from a Tertiary Care Hospital. J Clin Exp Hepatol (2016) 0.75
Frailty in HIV: Epidemiology, Biology, Measurement, Interventions, and Research Needs. Curr HIV/AIDS Rep (2016) 0.75
HIV/HCV Co-infection, Liver Disease Progression, and Age-Related IGF-1 Decline. Pathog Immun (2017) 0.75
HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals. J Clin Transl Hepatol (2016) 0.75
Insights on the Russian HCV Care Cascade: Minimal HCV Treatment for HIV/HCV Co-infected PWID in St. Petersburg. Hepatol Med Policy (2016) 0.75
Responder Interferon λ Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV-Hepatitis C Virus Coinfection. J Infect Dis (2016) 0.75
Barriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon Era. Open Forum Infect Dis (2017) 0.75
Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide. Pharmacol Res Perspect (2017) 0.75
High Hepatitis C cure rates among black and non-black HIV-infected adults in an urban center. Hepatology (2017) 0.75
Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there? J Int AIDS Soc (2017) 0.75
Models for longitudinal data: a generalized estimating equation approach. Biometrics (1988) 27.90
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Changes in thymic function with age and during the treatment of HIV infection. Nature (1998) 10.27
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet (1997) 10.05
Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab (2007) 9.77
Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology (2005) 9.44
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature (2011) 8.45
The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA (2000) 7.65
The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr (1991) 7.05
Telomere dysfunction induces metabolic and mitochondrial compromise. Nature (2011) 6.36
Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health (1996) 5.45
Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet (2003) 4.88
Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation (2004) 4.87
Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med (2010) 4.30
Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) (1995) 3.85
Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J (2002) 2.96
Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med (1995) 2.61
Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis (2012) 2.45
T cell telomere length in HIV-1 infection: no evidence for increased CD4+ T cell turnover. Science (1996) 2.12
The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology (2001) 1.87
Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis (2009) 1.80
Changes in blood-borne infection risk among injection drug users. J Infect Dis (2011) 1.74
End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood (2002) 1.73
Hepatitis C virus load and survival among injection drug users in the United States. Hepatology (2005) 1.66
Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology (2006) 1.63
Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med (1996) 1.59
HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies. Heart (2009) 1.42
Determinants of the quantity of hepatitis C virus RNA. J Infect Dis (2000) 1.32
HIV and premature aging: A field still in its infancy. Ann Intern Med (2010) 1.23
Telomerase activity of HIV-1-specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors. Blood (2008) 1.20
Progression to cirrhosis in hepatitis C patients: an age-dependent process. Liver Int (2007) 1.15
HIV infection in the etiology of lung cancer: confounding, causality, and consequences. Proc Am Thorac Soc (2011) 1.13
Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med (2002) 1.05
Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection. Gastroenterology (2009) 1.04
CD4+ T-lymphocyte telomere length is related to fibrosis stage, clinical outcome and treatment response in chronic hepatitis C virus infection. J Hepatol (2010) 0.93
Stability of liver fibrosis among HCV-infected injection drug users. Antivir Ther (2012) 0.89
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22
Perioperative mortality and long-term survival following live kidney donation. JAMA (2010) 7.34
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis (2004) 6.13
Protection against persistence of hepatitis C. Lancet (2002) 5.94
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (2002) 5.60
Exceeding the limits of liver histology markers. J Hepatol (2008) 5.06
Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A (2006) 4.54
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78
HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis (2007) 3.56
Hepatitis C and progression of HIV disease. JAMA (2002) 3.15
Occult hepatitis B. Lancet Infect Dis (2002) 3.09
Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis (2005) 3.06
IL28B and the control of hepatitis C virus infection. Gastroenterology (2010) 3.02
In vivo imaging of glucose uptake and metabolism in tumors. Nat Med (2013) 3.01
Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology (2008) 3.00
Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99
Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med (2005) 2.75
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 2.71
Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis (2004) 2.71
Hepatitis C in the HIV-Infected Person. Ann Intern Med (2003) 2.67
High HIV prevalence and risk behaviors in men who have sex with men in Chennai, India. J Acquir Immune Defic Syndr (2004) 2.66
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol (2005) 2.64
Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61
Needlestick transmission of hepatitis C. JAMA (2002) 2.55
Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology (2005) 2.52
HIV incidence determination in the United States: a multiassay approach. J Infect Dis (2012) 2.47
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology (2009) 2.45
Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS (2005) 2.34
Temporal trends in the incidence of human immunodeficiency virus infection and risk behavior among injection drug users in Baltimore, Maryland, 1988-1998. Am J Epidemiol (2002) 2.29
Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology (2009) 2.24
Survival of critically ill patients hospitalized in and out of intensive care units under paucity of intensive care unit beds. Crit Care Med (2004) 2.23
High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther (2011) 2.20
Incorrect identification of recent HIV infection in adults in the United States using a limiting-antigen avidity assay. AIDS (2014) 2.18
Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J Exp Med (2005) 2.16
Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology (2012) 2.14
Neighborhood poverty and injection cessation in a sample of injection drug users. Am J Epidemiol (2010) 2.07
Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis (2005) 2.02
Longitudinal predictors of injection cessation and subsequent relapse among a cohort of injection drug users in Baltimore, MD, 1988-2000. Drug Alcohol Depend (2005) 1.94
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS (2007) 1.92
Cross-genotype immunity to hepatitis C virus. J Virol (2004) 1.92
The effect of HIV infection on longitudinal lung function decline among IDUs: a prospective cohort. AIDS (2013) 1.92
Universal antiretroviral therapy for HIV infection: should US treatment guidelines be applied to resource-limited settings? Clin Infect Dis (2013) 1.92
Hepatitis C virus infection and incident type 2 diabetes. Hepatology (2003) 1.89
Behavioral risk exposure and host genetics of susceptibility to HIV-1 infection. J Infect Dis (2005) 1.89
Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA (2012) 1.88
Adherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, India. Clin Infect Dis (2007) 1.83
High pregnancy intentions and missed opportunities for patient-provider communication about fertility in a South African cohort of HIV-positive women on antiretroviral therapy. AIDS Behav (2012) 1.83
HLA-Cw*04 and hepatitis C virus persistence. J Virol (2002) 1.83
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS (2006) 1.82
High prevalence of HIV, HIV/hepatitis C virus coinfection, and risk behaviors among injection drug users in Chennai, India: a cause for concern. J Acquir Immune Defic Syndr (2008) 1.81
Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis (2009) 1.80
Survival of critically ill patients hospitalized in and out of intensive care. Crit Care Med (2007) 1.80
Changes in blood-borne infection risk among injection drug users. J Infect Dis (2011) 1.74
Peripheral blood count abnormalities among patients with hepatitis C in the United States. Hepatology (2002) 1.65
Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology (2006) 1.63
Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J Urban Health (2004) 1.62
High HIV burden among people who inject drugs in 15 Indian cities. AIDS (2015) 1.60
Treatment of intestinal worms is associated with decreased HIV plasma viral load. J Acquir Immune Defic Syndr (2002) 1.59
The effect of HIV infection on overdose mortality. AIDS (2005) 1.58
Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis (2010) 1.58
Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect Dis (2003) 1.57
Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology (2010) 1.53
Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection. J Virol (2003) 1.52